Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Study has two parts:
1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety
and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in
patients with advanced solid tumors.
2. Dose-expansion: to assess safety and tolerability of RAD001 and BEZ235 at the MTD in
patients with ER+/HER2- metastatic breast cancer and metastatic renal cell cancer